Abstract
Diabetes mellitus (DM) represents one of the most frequent comorbidities in patients with acromegaly. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent an important class for diabetes management. However, limited data is reported regarding the use of this class in patients with acromegaly and diabetes. Reporting data regarding patients with acromegaly and diabetes under treatment with SGLT2i. 29 acromegalic patients with diabetes were identified. Treatment with SGLT-2i was documented in nine patients, out of them 5 females and 4 males with a mean age (SD) of 61 ± 12 yr. The mean (SD) duration of treatment with SGLT2i was 27.5 ± 7.3 months. Mean HbA1c before and after SGLT-2i initiation was 8.1 ± 1.1 and 7.0 ± 0.9% respectively. Mean IGF-1 level (SD) before SGLT-2i initiation was 177 ± 68 ng/mL and the mean GH level (SD) was 0.7 ± 0.5 µg/L. All nine patients are still under treatment with SGLT2i and none of them had reported any adverse reaction related to SGLT2i. The present article provides us for the first time with new data regarding the use of SGLT2i among acromegalic patients with diabetes.
Highlights
Is a chronic disease generally caused by a GH-secreting pituitary adenoma [1]
The present article provides us for the first time with new data regarding the use of Sodium glucose cotransporter 2 inhibitors (SGLT2i) among acromegalic patients with diabetes
This important class with a unique mode of action is widely used in type 2 diabetes mellitus (T2DM) and recently was approved for patients with heart failure with reduced ejection fraction and for patients with chronic kidney disease (CKD) without diabetes [4, 5]
Summary
34 acromegalic patients with diabetes were identified. Treatment with SGLT-2i was documented in nine patients, out of them 5 females and 4 males with a mean age (SD) of 61± 12 yr. All nine patients are still under treatment with SGLT2i and none of them had reported any adverse reaction related to SGLT2i
Sign-in/Register to view highlights & summary 
Submitted Version (
Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call